A clot-dissolving tissue plasminogen activator (tPA), tenecteplase is now indicated ... Tenecteplase thus officially joins the other stroke thrombolytic approved stateside, alteplase (Activase ...

in patients who received tissue plasminogen activator (TPA) for acute stroke (data from the Safe Implementation of Thrombolysis in Stroke–International Stroke Thrombolysis Register) and control ...

Although the benefits of thrombolytic therapy are well established in patients younger than age 75 years with acute ST-elevation myocardial infarction, the value of thrombolytic treatment in ...

Thrombolytic therapy for ischemic stroke with tissue plasminogen activator (tPA) increases the risk of brain hemorrhage. In a Nature Medicine paper, Cheng et al. report that, in rodents ...

Fibrinolytic therapy, also known as thrombolytic therapy, is used to lyse acute blood clots by activating plasminogen, resulting in the formation of plasmin, which cleaves the fibrin cross-links ...